Cited by 37Smoking Behavior and CessationSubstance Abuse Treatment and OutcomesChronic Obstructive Pulmonary Disease (COPD) Research

Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo

Open access
Gonzales, David, Jorenby, Douglas E., Brandon, Thomas H., Arteaga, Carmen, Lee, Theodore C.·2010·Addiction

Abstract

AIMS: We assessed to what degree smokers who fail to quit on the target quit date (TQD) or lapse following TQD eventually achieve success with continued treatment. DESIGN: A secondary analysis of pooled data of successful quitters treated with varenicline (306 of 696), bupropion (199 of 671) and placebo (121 of 685) from two identically-designed clinical trials of varenicline versus bupropion sustained-release and placebo. SETTING: Multiple research centers in the US. PARTICIPANTS: Adult smokers (n==2052) randomized to 12 weeks drug treatment plus 40 weeks follow-up. MEASUREMENT: The primary end-point for the trials was continuous abstinence for weeks 9-12. TQD was day 8. Two patterns of successful quitting were identified. Immediate quitters (IQs) were continuously abstinent for weeks 2-12. Delayed quitters (DQs) smoked during 1 or more weeks for weeks 2-8. FINDINGS: Cumulative continuous abstinence (IQs + DQs) increased for all treatments during weeks 3-8. Overall IQs and DQs for varenicline were (24%; 20%) versus bupropion (18.0%, P=0.007; 11.6%, P<0.001) or placebo (10.2%, P<0.001; 7.5%, P<0.001). However, DQs as a proportion of successful quitters was similar for all treatments (varenicline 45%; bupropion 39%; placebo 42%) and accounted for approximately one-third of those remaining continuously abstinent for weeks 9-52. No gender differences were observed by quit pattern. Post-treatment relapse was similar across groups. CONCLUSIONS: Our data support continuing cessation treatments without interruption for smokers motivated to remain in the quitting process despite lack of success early in the treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1360-0443.2010.03058.x

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Gonzales, D., Jorenby, D. E., Brandon, T. H., Arteaga, C., & Lee, T. C.
Affiliations
  • Oregon Health & Science University (US)
  • University of Wisconsin–Madison (US)
  • Moffitt Cancer Center (US)
  • Pfizer (United States) (US)
Corresponding author
Gonzales, David
Venue
Addiction
Publisher
Wiley
Published
2010-09
Volume
105
Issue
11
Pages
2002-2013
ISSN
  • 0965-2140 (ISSN-L)
  • 1360-0443
OpenAlex
W1549904073
Cited by
37
References
34
Citations by year
2025: 1 · 2023: 5 · 2022: 2 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 4 · 2016: 2 · 2015: 5 · 2014: 2 · 2012: 7
FWCI
2.38
Type
journal article
Language
en
Open access
Locations
  • Addiction (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Smoking Behavior and Cessation
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
Keywords
smoking cessation, varenicline, bupropion sustained release, relapse, continuous abstinence, nicotine dependence
MeSH terms
Varenicline, Adolescent, Adult, Aged, Benzazepines, Breath Tests, Carbon Monoxide, Delayed-Action Preparations, Drug Labeling, Female, Humans, Health Knowledge, Attitudes, Practice, Male, Middle Aged, Motivation, Placebos, Quinoxalines, Smoking, Substance Withdrawal Syndrome, Time Factors, Logistic Models, Smoking Cessation, Bupropion, Treatment Outcome, Nicotinic Agonists, Dopamine Uptake Inhibitors, Secondary Prevention, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review